Cercar

01/09/2025 Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice
Butrón-Bris, B, Llamas-Velasco, M, Armesto, S, Sahuquillo-Torralba, A, Pujol-Montcusi, J, Ruiz-Villaverde, R, Martinez-López, A, de la Cueva, P, Romero-Mate, A, Roustan, G, Vilarrasa-Rull, E, Ferrán-Farres, M, Ovejero-Benito, MC, Palomar-Moreno, C, Navares, M, Novalbos, J, Abad-Santos, F, Dauden, E, de la Fuente, H. Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.03.030. PMID:40246146. IF:(Q/D).
01/09/2025 European Guideline (EuroGuiDerm) on atopic eczema: Living update
Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Barbarot, S, Bieber, T, Brough, HA, Calzavara-Pinton, P, Christen-Zaech, S, Deleuran, M, Dittmann, M, Fosse, N, Gáspár, K, Gerbens, LAA, Gieler, U, Girolomoni, G, Gregoriou, S, Holland, S, Mortz, CG, Nast, A, Nygaard, U, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Werner, RN, Flohr, C. European Guideline (EuroGuiDerm) on atopic eczema: Living update. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(9)DOI:10.1111/jdv.20639. PMID:40317496. IF:8.000(Q1/1D).
01/09/2025 Bimekizumab efficacy in patients with plaque psoriasis: A post hoc stratification by weight over 4 years in BE BRIGHT
Gkini, MA, López-Ferrer, A, Magnolo, N, Soung, J, Trafford, A, Pousa, ID, Kavanagh, S, Gooderham, M. Bimekizumab efficacy in patients with plaque psoriasis: A post hoc stratification by weight over 4 years in BE BRIGHT. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).
01/09/2025 Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Blauvelt, A, Langley, RG, Lebwohl, M, Strober, B, Warren, RB, Puig, L, Morita, A, Gordon, KB, Fernandez-Peña, P, Kavanagh, S, Pinto, JML, Lambert, J, Hoepken, B, Deherder, D, Cross, N, Thaçi, D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:10.1016/j.jaad.2025.04.038. PMID:40286813. IF:11.800(Q1/1D).
22/08/2025 Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis
Cantó, E, del Prado, ME, Vilarrasa, E, López-Ferrer, A, de Aranibar, FJGL, Ortiz, MA, Gut, M, Mulet, M, Esteve-Codina, A, Osuna-Gómez, R, Guinart-Cuadra, A, Puig, L, Vidal, S. Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(17)DOI:10.3390/ijms26178118. PMID:40943056. IF:4.900(Q1/3D).
01/07/2025 Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis
Salgado-Boquete, L, Puig, L, Carrascosa, JM, de la Cueva, P, Ferrer, AL. Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis. Actas Dermo-Sifiliograficas. 2025; 116(7)DOI:10.1016/j.ad.2025.05.011. PMID:40446921. IF:(Q/D).